LI Ying,ZHANG Zaoyu,DENG Rong,et al.Research progress on clinical and molecular mechanisms of Xianglian pills in the treatment of ulcerative colitis[J].ZHONGGUO YAOFANG,2025,36(20):2609-2614.
LI Ying,ZHANG Zaoyu,DENG Rong,et al.Research progress on clinical and molecular mechanisms of Xianglian pills in the treatment of ulcerative colitis[J].ZHONGGUO YAOFANG,2025,36(20):2609-2614. DOI: 10.6039/j.issn.1001-0408.2025.20.22.
Research progress on clinical and molecular mechanisms of Xianglian pills in the treatment of ulcerative colitis
Ulcerative colitis (UC) is a chronic intestinal autoimmune disease, with clinical manifestations
including abdominal pain, diarrhea, mucus and bloody stools, and its pathogenesis is complex. The classic prescription Xianglian pills (XLP) has been widely used in the clinical treatment of UC in recent years. It has few adverse reactions, good patient tolerance, and shows significant potential for clinical application. However, there is currently no comprehensive integration of evidence on its clinical research and molecular mechanisms. Through a systematic review of the clinical research and molecular mechanisms of XLP in the treatment of UC, it is found that XLP and its modified formulas, when used in combination with chemical drugs, can significantly improve the symptoms of UC patients and reduce intestinal inflammation, with superior efficacy compared to chemical drugs alone. Its mechanism of action involves regulating pan-apoptosis, immune response, signaling pathways (hypoxia-inducible factor-1α, nuclear factor-κB, etc.), intestinal flora, and repairing the intestinal mucosal barrier. Its medicinal materials, monomers and active components can also prevent the differentiation of helper T cells 17 and restore the balance of M1/M2 cells through regulating multiple pathways such as Wnt/
β
-catenin and Janus kinase/signal transducer and activator of transcription, thereby reducing intestinal damage in UC.
关键词
Keywords
references
YU Y R , RODRIGUEZ J R . Clinical presentation of Crohn’s,ulcerative colitis,and indeterminate colitis:symptoms,extraintestinal manifestations,and disease phenotypes [J ] . Semin Pediatr Surg , 2017 , 26 ( 6 ): 349 - 355 .
KOBAYASHI T , SIEGMUND B , LE BERRE C , et al . Ulcerative colitis [J ] . Nat Rev Dis Primers , 2020 , 6 : 74 .
Inflammatory Bowel Disease Group , Chinese Society of Gastroenterology , Chinese Medical Association , Inflammatory Bowel Disease Quality Control Center of China . 2023 Chinese national clinical practice guideline on diagnosis and management of ulcerative colitis [J ] . Chin Med J(Engl) , 2024 , 137 ( 14 ): 1642 - 1646 .
GUO H M , ZHANG J Z , GAO W Y , et al . Gastrointestinal effect of methanol extract of Radix Aucklandiae and selected active substances on the transit activity of rat isolated intestinal strips [J ] . Pharm Biol , 2014 , 52 ( 9 ): 1141 - 1149 .
DICARLO M , TETI G , VERNA G , et al . Quercetin exposure suppresses the inflammatory pathway in intestinal organoids from Winnie mice [J ] . Int J Mol Sci , 2019 , 20 ( 22 ): 5771 .
MOPARTHI L , KOCH S . Wnt signaling in intestinal inflammation [J ] . Differentiation , 2019 , 108 : 24 - 32 .
LUO Z Y , HU Y X , QIU C W , et al . Coptidis Rhizoma processed with Evodia rutaecarpa improves the effect on ulcerative colitis by increasing intestinal energy metabolites alpha-ketoglutarate and Lactobacillus reuteri [J ] . Phytomedicine , 2023 , 121 : 155115 .
HARRIS C , FRASER CUMMINGS J R . JAK1 inhibition and inflammatory bowel disease [J ] . Rheumatology (Oxford) , 2021 , 60 ( Suppl. 2 ):ii45-ii51.
LIU C S , XIA T , LUO Z Y , et al . Network pharmacology and pharmacokinetics integrated strategy to investigate the pharmacological mechanism of Xianglian pill on ulcera-tive colitis [J ] . Phytomedicine , 2021 , 82 : 153458 .
LI J Y , XIAO J , GAO M , et al . IRF/type Ⅰ IFN signaling serves as a valuable therapeutic target in the pathogenesis of inflammatory bowel disease [J ] . Int Immunopharmacol , 2021 , 92 : 107350 .
TIAN Y , YANG C M , YAO Q Y , et al . Procyanidin B2 activates PPARγ to induce M2 polarization in mouse macrophages [J ] . Front Immunol , 2019 , 10 : 1895 .
ZHOU H F , YANG C , LI J Y , et al . Quercetin serves as the major component of Xianglian pill to ameliorate ulcerative colitis via tipping the balance of STAT1/PPARγ and dictating the alternative activation of macrophage [J ] . J Ethnopharmacol , 2023 , 313 : 116557 .
LEE S , KARKI R , WANG Y Q , et al . AIM2 forms a complex with pyrin and ZBP1 to drive PANoptosis and host defence [J ] . Nature , 2021 , 597 ( 7876 ): 415 - 419 .
YANG Z H , LIN S S , FENG W Y , et al . A potential therapeutic target in traditional Chinese medicine for ulcerative colitis:macrophage polarization [J ] . Front Pharmacol , 2022 , 13 : 999179 .
WANG S L , LIU G H , LI Y R , et al . Metabolic reprogramming induces macrophage polarization in the tumor microenvironment [J ] . Front Immunol , 2022 , 13 : 840029 .
ZHANG J X , HU Y X , LIU Y , et al . Xianglian pill alle-viates ulcerative colitis by inhibiting M1 macrophage polari-zation via modulation of energy metabolite itaconate [J ] . Phytomedicine , 2024 , 135 : 156179 .
WU D S , CAO H , ZHANG Y , et al . Shaoyaotang treats ulcerative colitis by inhibiting HIF-1α and regulating Th17/Treg balance [J ] . Chin J Exp Tradit Med Formulae , 2021 , 27 ( 16 ).
WANG J Q , JEELALL Y S , FERGUSON L L , et al . Toll-like receptors and cancer:MyD88 mutation and inflammation [J ] . Front Immunol , 2014 , 5 : 367 .
DAI Y X , LU Q L , LI P Y , et al . Xianglian pill attenuates ulcerative colitis through TLR4/MyD88/NF-κB signaling pathway [J ] . J Ethnopharmacol , 2023 , 300 : 115690 .
NIGHOT P K , HU C A , MA T Y . Autophagy enhances intestinal epithelial tight junction barrier function by tar-geting claudin-2 protein degradation [J ] . J Biol Chem , 2015 , 290 ( 11 ): 7234 - 7246 .
BENTO C F , RENNA M , GHISLAT G , et al . Mammalian autophagy:how does it work? [J ] . Annu Rev Biochem , 2016 , 85 : 685 - 713 .
Frontiers Editorial Office . Retracted:Xianglian pill suppresses inflammation and protects intestinal epithelial barrier by promoting autophagy in DSS induced ulcerative colitis mice [J ] . Front Pharmacol , 2023 , 14 : 1289227 .
GUO X Y , LIU X J , HAO J Y . Gut microbiota in ulcera-tive colitis:insights on pathogenesis and treatment [J ] . J Dig Dis , 2020 , 21 ( 3 ): 147 - 159 .
LIU C S , HU Y X , LUO Z Y , et al . Xianglian pill modulates gut microbial production of succinate and induces regulatory T cells to alleviate ulcerative colitis in rats [J ] . J Ethnopharmacol , 2023 , 303 : 116007 .
CHANG J , LEONG R W , WASINGER V C , et al . Impaired intestinal permeability contributes to ongoing bowel symptoms in patients with inflammatory bowel di-sease and mucosal healing [J ] . Gastroenterology , 2017 , 153 ( 3 ): 723 - 731.e1 .
YANG L J , ZHANG Q , HUANG J Y , et al . Xianglian pill ameliorates antibiotic-associated diarrhea by restoring intestinal microbiota and attenuating mucosal damage [J ] . J Ethnopharmacol , 2021 , 264 : 113377 .